Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Q1 2025 Earnings Presentation
9 slides from Coloplast A/s Class B's earnings presentation, Feb 4, 2025
Slide 1: Making life easier
Conference call presentation Q1 2024/25 Making life easier Strive25: Sustainable Growth Leadership Michel, User, Continence Care Ostomy Care | Continence Care | Advanced Wound Care | Interventional Urology | Voice and Respiratory Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Q1 2024/25 financial result in line with expectations
NEW IMAGE Q1 2024/25 financial result Otto: add picture in line with expectations with Peristeen Light Update Update picture picture Organic Reported Adjusted ROIC growth EBIT margin 8% 27% * * 15% ** Update picture *before special items **after tax and before special items. Adjusted for extraordina
Slide 4: Q1 organic growth of 8% driven by Chronic Care and double-digit growth in Advanced Wound Care and Voice & Respiratory Care
Q1 organic growth of 8% was driven by Chronic Care and double-digit growth in Advanced Wound Care and Voice & Respiratory Care Q1 2024/25 revenue by business area Q1 2024/25 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Shar
Slide 5: Q1 reported revenue grew 6% with divestment and currency detraction
Q1 reported revenue grew 6% with ~1%-point detraction from divested operations and ~1%-point negative impact from currencies Q1 2024/25 Revenue development (mDKK) Q1 2024/25 highlights • Reported revenue increased by DKK 420 million or 6% vs. last year. • Organic growth was 8% or DKK 499 million, dr
Slide 6: EBIT margin of 27% in Q1, as expected
EBIT margin of 27%1 in Q1, as expected, driven by a higher level of distribution costs and currency headwind Q1 2024/25 EBIT margin development before special items (%) Q1 2024/25 highlights • Gross margin was 68%, on par with last year. • Positive impact from a favourable development in input costs
Slide 7: Q1 adjusted FCF was DKK 1,682 million with FCF-to-sales ratio of 24%
Q1 adjusted FCF was DKK 1,682 million with a FCF-to-sales ratio of 24%, reflecting improved operating cash flow FCF development1 Q1 2024/25 highlights • Free cash flow for Q1 2024/25 was an inflow of DKK 1,874 million, compared to an inflow of DKK 1,521 million last year, or a 23% increase. 90 93 Fr
Slide 8: FY 2024/25 financial guidance: unchanged organic growth and EBIT margin
FY 2024/25 financial guidance: unchanged organic growth of 8-9% and an EBIT margin before special items of around 28% Organic revenue growth 8-9% Reported revenue growth in DKK Around 7% Reported EBIT margin* Around 28% Effective tax rate** Around 40% (Ordinary tax rate) (Around 22%) Capital expendi
Slide 9: Mission, values and vision
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding